OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Luciana Mosca, Andrea Ilari, Francesco Fazi, et al.
Drug Resistance Updates (2021) Vol. 54, pp. 100742-100742
Closed Access | Times Cited: 218
Luciana Mosca, Andrea Ilari, Francesco Fazi, et al.
Drug Resistance Updates (2021) Vol. 54, pp. 100742-100742
Closed Access | Times Cited: 218
Showing 1-25 of 218 citing articles:
Therapeutic strategies to overcome taxane resistance in cancer
Tuyelee Das, Uttpal Anand, Swaroop Kumar Pandey, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100754-100754
Closed Access | Times Cited: 143
Tuyelee Das, Uttpal Anand, Swaroop Kumar Pandey, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100754-100754
Closed Access | Times Cited: 143
Novel nanomedicines to overcome cancer multidrug resistance
Zhenwei Su, Shaowei Dong, Shan‐Chao Zhao, et al.
Drug Resistance Updates (2021) Vol. 58, pp. 100777-100777
Closed Access | Times Cited: 134
Zhenwei Su, Shaowei Dong, Shan‐Chao Zhao, et al.
Drug Resistance Updates (2021) Vol. 58, pp. 100777-100777
Closed Access | Times Cited: 134
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1796-1796
Open Access | Times Cited: 111
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1796-1796
Open Access | Times Cited: 111
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Xiaojing Du, Biwei Yang, Quanlin An, et al.
The Innovation (2021) Vol. 2, Iss. 2, pp. 100103-100103
Open Access | Times Cited: 109
Xiaojing Du, Biwei Yang, Quanlin An, et al.
The Innovation (2021) Vol. 2, Iss. 2, pp. 100103-100103
Open Access | Times Cited: 109
Long non-coding RNA mediated drug resistance in breast cancer
Deepshikha Singh, Yehuda G. Assaraf, Rajesh N. Gacche
Drug Resistance Updates (2022) Vol. 63, pp. 100851-100851
Closed Access | Times Cited: 83
Deepshikha Singh, Yehuda G. Assaraf, Rajesh N. Gacche
Drug Resistance Updates (2022) Vol. 63, pp. 100851-100851
Closed Access | Times Cited: 83
Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer
Reyhaneh Farghadani, Rakesh Naidu
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2144-2144
Open Access | Times Cited: 73
Reyhaneh Farghadani, Rakesh Naidu
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2144-2144
Open Access | Times Cited: 73
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents
Enrique Domínguez‐Álvarez, Bálint Rácz, Małgorzata Anna Marć, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100844-100844
Open Access | Times Cited: 66
Enrique Domínguez‐Álvarez, Bálint Rácz, Małgorzata Anna Marć, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100844-100844
Open Access | Times Cited: 66
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria
Xiaoqing Xie, Yi Yang, Qiang Wang, et al.
Cell Research (2023) Vol. 33, Iss. 3, pp. 215-228
Open Access | Times Cited: 50
Xiaoqing Xie, Yi Yang, Qiang Wang, et al.
Cell Research (2023) Vol. 33, Iss. 3, pp. 215-228
Open Access | Times Cited: 50
Beyond matrix stiffness: targeting force-induced cancer drug resistance
Maria Kalli, Matthew D. Poskus, Triantafyllos Stylianopoulos, et al.
Trends in cancer (2023) Vol. 9, Iss. 11, pp. 937-954
Open Access | Times Cited: 46
Maria Kalli, Matthew D. Poskus, Triantafyllos Stylianopoulos, et al.
Trends in cancer (2023) Vol. 9, Iss. 11, pp. 937-954
Open Access | Times Cited: 46
Strategies and Lessons Learned from Total Synthesis of Taxol
Long Min, Jing‐Chun Han, Wen Zhang, et al.
Chemical Reviews (2023) Vol. 123, Iss. 8, pp. 4934-4971
Closed Access | Times Cited: 43
Long Min, Jing‐Chun Han, Wen Zhang, et al.
Chemical Reviews (2023) Vol. 123, Iss. 8, pp. 4934-4971
Closed Access | Times Cited: 43
Interactions and communications in lung tumor microenvironment: Chemo/radiotherapy resistance mechanisms and therapeutic targets
Feng Yuan, Ying Jiang, Lin Yang, et al.
Journal of drug targeting (2025), pp. 1-33
Closed Access | Times Cited: 1
Feng Yuan, Ying Jiang, Lin Yang, et al.
Journal of drug targeting (2025), pp. 1-33
Closed Access | Times Cited: 1
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
Lingyue Gao, Zhuo‐Xun Wu, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2021) Vol. 57, pp. 100770-100770
Closed Access | Times Cited: 93
Lingyue Gao, Zhuo‐Xun Wu, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2021) Vol. 57, pp. 100770-100770
Closed Access | Times Cited: 93
Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities
Yichang Ren, Yuxi Wang, Gang Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 8, pp. 4498-4515
Closed Access | Times Cited: 80
Yichang Ren, Yuxi Wang, Gang Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 8, pp. 4498-4515
Closed Access | Times Cited: 80
Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)
Meghana Manjunath, Bibha Choudhary
Oncology Letters (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 71
Meghana Manjunath, Bibha Choudhary
Oncology Letters (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 71
Asymmetric Total Synthesis of Taxol
Ya‐Jian Hu, Chen‐Chen Gu, Xin‐Feng Wang, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 42, pp. 17862-17870
Closed Access | Times Cited: 71
Ya‐Jian Hu, Chen‐Chen Gu, Xin‐Feng Wang, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 42, pp. 17862-17870
Closed Access | Times Cited: 71
Platinum drugs and taxanes: can we overcome resistance?
Elena V. Sazonova, Gelina S. Kopeina, Evgeny N. Imyanitov, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 57
Elena V. Sazonova, Gelina S. Kopeina, Evgeny N. Imyanitov, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 57
Chemopreventive effects of hesperidin against paclitaxel-induced hepatotoxicity and nephrotoxicity via amendment of Nrf2/HO-1 and caspase-3/Bax/Bcl-2 signaling pathways
Cihan Gür, Fatih Mehmet Kandemir, Cüneyt Çağlayan, et al.
Chemico-Biological Interactions (2022) Vol. 365, pp. 110073-110073
Closed Access | Times Cited: 54
Cihan Gür, Fatih Mehmet Kandemir, Cüneyt Çağlayan, et al.
Chemico-Biological Interactions (2022) Vol. 365, pp. 110073-110073
Closed Access | Times Cited: 54
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability
Giasemi C. Eptaminitaki, Dimitris Stellas, Benjamin Bonavida, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100866-100866
Closed Access | Times Cited: 49
Giasemi C. Eptaminitaki, Dimitris Stellas, Benjamin Bonavida, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100866-100866
Closed Access | Times Cited: 49
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment
Junnan Li, Lipeng Zhu, Hang Fai Kwok
Drug Resistance Updates (2022) Vol. 66, pp. 100904-100904
Closed Access | Times Cited: 48
Junnan Li, Lipeng Zhu, Hang Fai Kwok
Drug Resistance Updates (2022) Vol. 66, pp. 100904-100904
Closed Access | Times Cited: 48
Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials
Syed Nasir Abbas Bukhari
Pharmaceutics (2022) Vol. 14, Iss. 4, pp. 866-866
Open Access | Times Cited: 46
Syed Nasir Abbas Bukhari
Pharmaceutics (2022) Vol. 14, Iss. 4, pp. 866-866
Open Access | Times Cited: 46
Curcumin Induces Apoptosis of Chemoresistant Lung Cancer Cells via ROS-Regulated p38 MAPK Phosphorylation
Ming‐Fang Wu, Yen-Hsiang Huang, Ling‐Yen Chiu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8248-8248
Open Access | Times Cited: 46
Ming‐Fang Wu, Yen-Hsiang Huang, Ling‐Yen Chiu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8248-8248
Open Access | Times Cited: 46
Paclitaxel resistance related to nuclear envelope structural sturdiness
Elizabeth R. Smith, Jing‐Quan Wang, Dong‐Hua Yang, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100881-100881
Closed Access | Times Cited: 46
Elizabeth R. Smith, Jing‐Quan Wang, Dong‐Hua Yang, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100881-100881
Closed Access | Times Cited: 46
Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies
Yan Li, Chen Xu, Bing Wang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Yan Li, Chen Xu, Bing Wang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Current and emerging therapies for neuroendocrine prostate cancer
Busola R. Alabi, Shiqin Liu, Tanya Stoyanova
Pharmacology & Therapeutics (2022) Vol. 238, pp. 108255-108255
Closed Access | Times Cited: 38
Busola R. Alabi, Shiqin Liu, Tanya Stoyanova
Pharmacology & Therapeutics (2022) Vol. 238, pp. 108255-108255
Closed Access | Times Cited: 38
Substances of Natural Origin in Medicine: Plants vs. Cancer
Adrianna Gielecińska, Mateusz Kciuk, Somdutt Mujwar, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 986-986
Open Access | Times Cited: 32
Adrianna Gielecińska, Mateusz Kciuk, Somdutt Mujwar, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 986-986
Open Access | Times Cited: 32
